Feedback / Questions
neldaleucel (MT-601) - Marker Therap
https://www.globenewswire.com/news-release/2025/06/17/3100607/0/en/Marker-Therapeutics-and-Cellipont-Bioservices-Announce-Collaboration-to-Advance-cGMP-Manufacturing-of-MT-601-a-Multi-Antigen-Recognizing-T-Cell-Therapy-for-Patients-with-Lymphoma.html
Jun 17, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next